A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer

Inclusion Criteria:

• Epithelial carcinoma of ovarian, peritoneal or fallopian tube origin.
• Female
• age above 18 years
• WHO performance status 0-2
• Life expectancy > 3 months
• Previous treatment with one platinum and taxane containing regimen.
• Platinum and taxane sensitive relapse
• At least one evaluable/measurable lesion.
• Adequate hematologic, renal and liver function
• Consent form signed and dated before inclusion

Exclusion Criteria:

• Prior treatment with more than one line of chemotherapy
• Concurrent severe and/or uncontrolled co-morbid medical condition.
• History of previous or concurrent malignancy within the previous 5 years • History of prior serious allergic reactions such as anaphylactic shock
• Pregnant or lactating women (or potentially fertile women not using adequate contraception)
• Peripheral neuropathy > Grade 2
• History of allergy to drugs containing the excipient TWEEN 80®.
• Concomitant administration of any other experimental drug under investigation or concurrent treatment with any other anti-cancer therapy
• Clinical evidence of brain metastases